Literature DB >> 10404013

Midkine is expressed during repair of bone fracture and promotes chondrogenesis.

S Ohta1, H Muramatsu, T Senda, K Zou, H Iwata, T Muramatsu.   

Abstract

Midkine (MK) is a heparin-binding growth/differentiation factor implicated in the control of development and repair of various tissues. Upon fracture of the murine tibia, MK was found to be transiently expressed during bone repair. MK was immunohistochemically detected in spindle-shaped mesenchymal cells at the fracture site on day 4 after fracture and in chondrocytes in the area of endochondral ossification on day 7. MK expression was decreased on day 14 and scarcely seen on day 28 when bone repair was completed. This mode of MK expression is reminiscent of MK expression during development. MK was expressed in hypertrophic chondrocytes of the prebone cartilage rudiments on embryonic day 14 in mouse embryos. MK was also strongly expressed in the epiphyseal growth plate. MK was localized intracellularly during both bone repair and development, and this localization was confirmed by immunoelectron microscopy for embryonic chondrocytes. When MK cDNA was transfected into ATDC5 chondrogenic cells and overexpressed, the majority of transfected cells with strong MK expression showed enhanced chondrogenesis as revealed by increased synthesis of sulfated glycosaminoglycans, aggrecan, and type II collagen. These results suggest that MK plays important roles in chondrogenesis and contributes to bone formation and repair.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404013     DOI: 10.1359/jbmr.1999.14.7.1132

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  17 in total

1.  Nuclear targeting by the growth factor midkine.

Authors:  Yoshihisa Shibata; Takashi Muramatsu; Makoto Hirai; Tatsuya Inui; Terutoshi Kimura; Hidehiko Saito; Lynn M McCormick; Guojun Bu; Kenji Kadomatsu
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

Review 2.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Recombinant human midkine stimulates proliferation of articular chondrocytes.

Authors:  Z H Zhang; H X Li; Y P Qi; L J Du; S Y Zhu; M Y Wu; H L Lu; Y Yu; W Han
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

4.  Expression of the heparin-binding growth factors Midkine and pleiotrophin during ocular development.

Authors:  Ruda Cui; Peter Lwigale
Journal:  Gene Expr Patterns       Date:  2019-02-27       Impact factor: 1.224

5.  Expression and purification of bioactive high-purity human midkine in Escherichia coli.

Authors:  Zhong-hui Zhang; Li-juan Du; Di Xiang; Shun-ying Zhu; Ming-yuan Wu; Hui-li Lu; Yan Yu; Wei Han
Journal:  J Zhejiang Univ Sci B       Date:  2009-02       Impact factor: 3.066

6.  Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation.

Authors:  A J Brown; M Alicknavitch; S S D'Souza; T Daikoku; C B Kirn-Safran; D Marchetti; D D Carson; M C Farach-Carson
Journal:  Bone       Date:  2008-06-06       Impact factor: 4.398

7.  Cellular expression of midkine-a and midkine-b during retinal development and photoreceptor regeneration in zebrafish.

Authors:  Anda-Alexandra Calinescu; Thomas S Vihtelic; David R Hyde; Peter F Hitchcock
Journal:  J Comp Neurol       Date:  2009-05-01       Impact factor: 3.215

Review 8.  The role of midkine in skeletal remodelling.

Authors:  A Liedert; T Schinke; A Ignatius; M Amling
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 9.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

10.  The effects of early exercise on brain damage and recovery after focal cerebral infarction in rats.

Authors:  F Matsuda; H Sakakima; Y Yoshida
Journal:  Acta Physiol (Oxf)       Date:  2011-02       Impact factor: 6.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.